The role of neuregulin/ErbB2/ErbB4 signaling in the heart with special focus on effects on cardiomyocyte proliferation

Brian Wadugu1 and Bernhard Kühn1,2,3

1Department of Cardiology, Children’s Hospital Boston, Boston, Massachusetts; 2Department of Pediatrics, Harvard Medical School, Boston, Massachusetts; and 3Harvard Stem Cell Institute, Cambridge, Massachusetts

Submitted 23 January 2012; accepted in final form 14 March 2012

Wadugu B, Kühn B. The role of neuregulin/ErbB2/ErbB4 signaling in the heart with special focus on effects on cardiomyocyte proliferation. Am J Physiol Heart Circ Physiol 302: H2139–H2147, 2012. First published March 16, 2012; doi:10.1152/ajpheart.00063.2012.—The signaling complex consisting of the growth factor neuregulin-1 (NRG1) and its tyrosine kinase receptors ErbB2 and ErbB4 has a critical role in cardiac development and homeostasis of the structure and function of the adult heart. Recent research results suggest that targeting this signaling complex may provide a viable strategy for treating heart failure. Clinical trials are currently evaluating the effectiveness and safety of intravenous administration of recombinant NRG1 formulations in heart failure patients. Endogenous as well as administered NRG1 has multiple possible activities in the adult heart, but how these are related is unknown. It has recently been demonstrated that NRG1 administration can stimulate proliferation of cardiomyocytes, which may contribute to repair failing hearts. This review summarizes the current knowledge of how NRG1 and its receptors control cardiac physiology and biology, with special emphasis on its role in cardiomyocyte proliferation during myocardial growth and regeneration.

Cardiac repair; cardiac regeneration; cardiomyocyte differentiation

THIS ARTICLE is part of a collection on Physiological Basis of Cardiovascular Cell and Gene Therapies. Other articles appearing in this collection, as well as a full archive of all collections, can be found online at http://ajpheart.physiology.org/.

Introduction

Heart failure is a significant and growing public health problem worldwide (74). Although new therapies have improved patient outcomes, symptomatic heart failure is still a chronically progressive disease. Exciting advances have been made with cell (32, 43, 53, 83, 94) and gene therapy (48) approaches to treat heart failure. However, few drugs targeting novel pathways for addressing heart failure are in the development pipeline (49).

One new strategy for treating heart failure, which has shown promising results in animals, targets the signaling complex of the growth factor neuregulin-1 (NRG1) and its tyrosine kinase receptors, ErbB2 and ErbB4 (39, 72, 76, 91, 92). Clinical trials have been performed (26, 42) and are proceeding to determine the effectiveness and safety of intravenous administration of recombinant NRG1 formulations for treating congestive heart failure (ClinicalTrials.gov identifiers NCT01131637, NCT01258387). However, the translation of NRG1 administration into a successful clinical therapy requires that the underlying molecular and cellular mechanisms be identified and compared and their relation to one another be characterized.

Overexpression of the NRG1 receptor subunit ErbB2 promotes uncontrolled cancer growth, and ErbB2 inhibition by Herceptin (trastuzumab) is used to treat some types of cancer. One of the side effects of trastuzumab is cardiac dysfunction (85), suggesting a possible role of endogenous NRG1 and its receptors in maintaining cardiac structure and function in adults, which was the subject of excellent recent reviews (18, 25, 34, 76). In this review, we will examine the activities and roles of NRG1 and its receptor, the tyrosine kinase heterodimer ErbB2/ErbB4, in the myocardium, focusing on their role in cardiomyocyte proliferation. Despite the long-standing controversy over to what extent adult cardiomyocytes can progress through the cell cycle (2, 66, 70), recent studies have shown that a small subpopulation can be induced to proliferate in animals (6, 10, 23, 51, 71, 73, 96) and possibly in humans (5). NRG1 is one of a small group of extracellular factors known to control this process in animals (6, 22, 23, 51, 73). The induction of cardiomyocyte proliferation for stimulating myocardial repair provides a potential new mechanism of treatment for heart failure.

Address for reprint requests and other correspondence: B. Kühn, Dept. of Cardiology, Children’s Hospital Boston, 300 Longwood Ave., Enders 1212, Boston, MA, 02115 (e-mail: bkuhn@enders.tch.harvard.edu).
A potential protein therapy approach to stimulate myocardial repair may be complementary to cell transplantation approaches, and some features may offer unique advantages. For example, since resident cells would be stimulated to proliferate, a cell source or invasive procedures for procuring and/or implanting them would not be necessary. Furthermore, daughter cells of cardiomyocytes would inherit electromechanical connections from their mother cells, guaranteeing electrical and mechanical connections to the surrounding myocardium. The duration of the effect of recombinant factors can be controlled by dose and timing of administration. In addition, since cardiomyocytes are differentiated cells and primary myocardial tumors are exceedingly rare, malignant transformation would be unlikely. Thus, if it can be translated to the clinic, administration of recombinant proteins for the stimulation of cardiac repair has several promising features (36, 47).

NRG1/ErbB Signaling Is Critical in the Nervous System, Breast, and Heart

NRG1, a member of the epidermal growth factor (EGF) family, is known to control a plethora of mechanisms in epithelial, glial, neuronal, and heart muscle cells during development. NRG1 performs different functions in different types of cells: differentiation of neuronal cells (neuronal differentiation factor), accumulation of acetylcholine receptors in skeletal muscle (acetylcholine receptor-inducing activity), and proliferation of glial cells (glial growth factor). One possible way of summarizing these diverse cellular effects is that NRG1/ErbB signaling affects developmental cell fate decisions (9).

The NRG1 mRNA is transcribed from one gene, located on chromosome 8 in both mice and humans. The gene product is classified into three subgroups (I–III), which are processed as transmembranous proteins containing EGF-like domains [Fig. 1, and Olayanoye et al. (68)]. Type I and II NRG1 are cleaved by metallocproteinases into soluble forms and thus act as a paracrine factors. Type III is cleaved in such a way that the extracellular EGF domain remains attached to the transmembrane domain through the cysteine-rich domain to signal in the immediate environment (Fig. 1).

NRG1 acts through the receptor tyrosine kinases ErbB2, ErbB3, and ErbB4, which belong to the EGF-receptor family (14). Cardiomyocytes in the adult myocardium have been shown to express ErbB4 and ErbB2 (97). NRG1 binds to ErbB4 with high affinity, which in cardiomyocytes is believed to dimerize preferentially with ErbB2. In ErbB2/ErbB4 heterodimers, ErbB2 functions as a “nonautonomous amplifier” (14) by providing a very active kinase domain.

Ligand-binding to ErbB4 and dimerization with ErbB2 leads to signal transduction through the transmembrane helixes and activation of the intracellular kinase domain, leading to tyrosine phosphorylation. The phosphorylated intracellular domains then recruit signaling proteins containing phosphotyrosine-binding and Src homology-2 domains. In adult cardiomyocytes, phosphatidylinositol 3-kinase (19, 24), Src (52), and ShcA (86) are important effector molecules of ErbB2/ErbB4 signaling (Fig. 1). These proteins relay the signal to downstream signaling pathways, which regulate a variety of cell-specific functions, including differentiation, proliferation, and cell migration (14).

The ErbB4 gene is located on chromosome 1 in mice and 2 in humans. Post-transcriptional processing of the ErbB4 gene product is complex, including alternative splicing and regulated cleavage by proteases (14, 87). Alternative splicing gives rise to multiple isoforms. One splice variant of ErbB4 cannot be cleaved by matrix metalloproteinases in the juxtamembrane region and is referred to as juxtamembrane domain variant b (21). Only this variant is expressed in the adult mouse myocardium (21). Another splice variant has differential intracellular signaling to phosphatidylinositol 3-kinase and is referred to as CYT-2 (20). The functional relevance of the different splice variants in the heart is currently unknown.

Although NRG1 is a high-affinity ligand for ErbB4, it should be noted that NRG2, NRG3, NRG4, HB-EGF, and ephregulin can also activate ErbB4 (14, 93). HB-EGF has been

![Fig. 1. Structure and function of neuregulin-1 (NRG1) and ErbB4, diagrammatically depicted in two neighboring cells. Type I–III NRG1s have epidermal growth factor-like domains (EGF). Type I/II NRG1s have a heparin-binding domain (HBD) whereas type III have a cysteine-rich domain (CRD). Both types may be subject to cleavage by a member of proteins containing a disintegrin and a metalloproteinase domain (ADAM). Type III is released and functions as a paracrine factor. Type III remains a transmembranous protein through the CRD. NRG1/ErbB4 signaling is initiated by binding of NRG1 to ErbB4, which increases kinase activity and downstream signaling via multiple pathways. In the heart, the following pathways have been shown to be activated by NRG1: 1) Src and focal adhesion kinase (FAK); 2) Src homology domain-containing protein (ShcA) and mitogen-activated protein kinases (MAPK); and 3) phosphatidylinositol 3-kinase (PI3K) and Akt.

H2140 NEUREGULIN1/ErbB4 SIGNALING AND CARDIOMYOCYTE PROLIFERATION

AJP-Heart Circ Physiol • doi:10.1152/ajpheart.00063.2012 • www.ajpheart.org
connected to cardiac hypertrophy (41, 79), but the extent to which the other alternative ligands contribute to ErbB signaling in the heart is largely unknown.

**Effects of NRG1 Administration on Cardiac Structure and Function**

Multiple studies that have evaluated the NRG1/ErbB axis in cardiomyocytes, animal models, and two clinical trials are discussed throughout this review and summarized in Table 1. A preclinical study showed that intravenous administration of recombinant NRG1 improved cardiac function and prolonged survival in animal models of ischemic, dilated, and viral cardiomyopathy (60). In this study, NRG1 was administered in rats after experimental myocardial infarction (MI) daily for 10 days beginning 1 or 8 wk after MI. NRG1-injected animals showed improved ejection fraction (EF) as well as a smaller end-diastolic dimension. In an additional experiment, recombinant NRG1 was administered in rats beginning 1 wk after MI for 10 days in conjunction with angiotensin-converting enzyme (ACE) inhibitor therapy (60). The functional effects in this study, determined by hemodynamic catheterization 3 wk later, appeared to be additive, and in the survival analysis, NRG1 and ACE inhibitors showed an additive effect as well. This study also used a rat doxorubicin cardiomyopathy model and a mouse model of Coxsackie-virus myocarditis, both of which showed that NRG1 administration improved function and reduced tissue damage determined by semiquantitative histopathological examination. Furthermore, this study used a dog-pacing model, in which administration of NRG1 for 10 consecutive days showed functional improvements. The NRG1 effect was still detectable 3 wk later, suggesting that NRG1 administration may induce not only functional but also structural improvements.

**In a human cohort trial of 15 patients with ischemic heart disease and idiopathic dilative cardiomyopathy (mean age, 60 yr; New York Heart Association classes II and III; mean EF, 32%; and standard medical therapy), NRG1 was administered by daily intravenous infusions for 10 consecutive days (42). The EF, measured by cardiac magnetic resonance imaging, improved by 4%, which is in the range of what has been reported after stem cell transplantation (4, 78). The patients showed sustained improvement of the EF for a follow-up period of 80 days.

A double-blinded, randomized controlled trial of 44 patients with congestive heart failure (New York Heart Association classes II and III; EF < 40% by echocardiography; and acute MI was excluded) tested three different doses of intravenous NRG1 (0.3, 0.6, 1.2 μg/kg) given for 10 consecutive days versus standard medical therapy (26). The effects were determined by cardiac magnetic resonance imaging, which showed significant improvements of the EF and left ventricular volumes only in the 0.6 μg/kg dose group. These improvements were sustained for 90 days, suggesting lasting effects of the NRG1 administration beyond the immediate period following the infusions.

To become an acceptable therapeutic approach, the design of the animal and human studies of NRG1 administration needs to be optimized to advance the promising results observed to date. Achieving this goal may require developing greater understanding of the underlying cellular and molecular effects and mechanisms. This knowledge could answer questions about which target cells are directly and indirectly affected, what cellular responses occur after administration, and what signaling mechanisms are involved. Advanced knowledge of these mechanisms would provide essential information for conducting future basic, translational, and clinical research studies.

Table 1. Summary of studies of NRG1 administration in in vitro systems, animal models, and humans with relation to cardiomyocyte proliferation and differentiation and cardiac physiology and repair

<table>
<thead>
<tr>
<th>System</th>
<th>Formulation</th>
<th>Amino Acids</th>
<th>Administration</th>
<th>Measured Effects</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>E12.5 mouse embryo culture</td>
<td>NRG1-β1</td>
<td>177–244</td>
<td>Injection of 50 ng per embryo, incubation in 50% rat serum 30 ng/ml</td>
<td>Stimulates formation of trabeculae and cardiomyocyte DNA synthesis; Cardiomyocyte DNA synthesis,</td>
<td>(35)</td>
</tr>
<tr>
<td></td>
<td>GGF2</td>
<td>Not provided</td>
<td>2–246</td>
<td>embryonic cardiomyocyte proliferation; Cardiomyocyte DNA synthesis, karyokinesis, and cytokinesis</td>
<td>(97)</td>
</tr>
<tr>
<td>Cultured embryonic rat ventricular cardiomyocytes</td>
<td>NRG1-β1</td>
<td>Not provided</td>
<td>50 ng/ml</td>
<td>Cardiomyocyte DNA synthesis, karyokinesis, cytokinesis, and division</td>
<td></td>
</tr>
<tr>
<td>Primary adult rat ventricular cardiomyocytes</td>
<td>NRG1-β1</td>
<td>176–246</td>
<td>0.001–0.1 μg/ml</td>
<td>Cardiomyocyte DNA synthesis, karyokinesis, cytokinesis, and division</td>
<td></td>
</tr>
<tr>
<td>Primary adult rat ventricular cardiomyocytes</td>
<td>NRG1-β1</td>
<td>176–246</td>
<td>100 μg/kg ip, for 12 wk</td>
<td>Cardiomyocyte DNA synthesis, karyokinesis, cytokinesis, and division</td>
<td></td>
</tr>
<tr>
<td>Mouse, post-MI</td>
<td>NRG1-β2a</td>
<td>177–237</td>
<td>3–30 μg/kg iv for 5 days</td>
<td>Improvement of function compared with angiotensin converting enzyme-blocker; 10% EF improvement</td>
<td>(26)</td>
</tr>
<tr>
<td>Multiple animal models</td>
<td>NRG1-β2a</td>
<td>177–237</td>
<td>0.3–1.2 μg·kg⁻¹·day⁻¹ iv for 10 days</td>
<td>EF improvement (nonsignificant); 4% EF improvement after therapy compared with baseline (P &lt; 0.001)</td>
<td>(42)</td>
</tr>
<tr>
<td><strong>Controlled human trial</strong></td>
<td>NRG1-β2a</td>
<td>177–237</td>
<td>0.6–1.2 μg·kg⁻¹·day⁻¹ iv for 10 days</td>
<td>4% EF improvement 12 wk after therapy compared with baseline (P &lt; 0.001)</td>
<td></td>
</tr>
</tbody>
</table>

This table may serve as a tool to compare different studies that are discussed throughout this review. Examples are ordered from development to adult and from in vitro to in vivo studies. The third column lists the amino acids corresponding to the human sequence. E12.5, embryonic day 12.5; MI, myocardial infarction; NRG1, neuregulin-1; GGF2, glial growth factor 2; EF, ejection fraction, values are absolute values, not percent changes; EDD, end-diastolic dimension; EDV, end-diastolic volume; CMR, cardiac magnetic resonance imaging.
NRG1 and Its Receptors Control Prenatal Myocardial Development

The germline knockouts (KOs) of the NRG1, ErbB2, and ErbB4 genes all showed very similar cardiac phenotypes, i.e., the ventricular myocardial wall was thin at embryonic day (E) 9.5–10.5, leading to fetal demise (28, 55, 64). More specifically, the inner, trabecular layer of myocardium, which arises from the outer, compact layer, was thin. While NRG1 is required for myocardial trabeculation, bone morphogenetic protein 10 was identified as an important factor stimulating cardiomyocyte proliferation at E9.5 in mice (30). A zebrafish ErbB2 mutant (59) also lacked myocardial trabeculations. The accessibility of zebrafish larvae for microscopic imaging allowed the investigators to determine that altered cardiomyocyte delamination was the likely underlying cellular mechanism. Complex gene regulatory mechanisms, which connect NRG1/ErbB signaling with myocardial trabeculation, have been identified in mice (54). It is important to note that proliferation and differentiation, which are mutually exclusive in skeletal muscle cells, occur simultaneously in cardiomyocytes. Thus, collectively, these findings suggest that NRG1, ErbB2, and ErbB4 are involved in controlling cardiomyocyte differentiation and migration during cardiac morphogenesis.

In cultured embryonic rat cardiomyocytes, the addition of NRG1 stimulated DNA synthesis and proliferation (97). In an embryonic heart ex vivo culturing system, the addition of NRG1 stimulated formation of trabeculae (35), which is in agreement with the phenotype of the KOs. These results support the notion that the complex of NRG1, ErbB2, and ErbB4 controls cardiomyocyte proliferation and differentiation during development. In addition, NRG1 stimulates the generation of working-type cardiomyocytes in embryonic stem cell cultures (84, 89, 98), indicating that NRG1 may also stimulate formation of cardiomyocytes from undifferentiated stem and progenitor cells.

In summary, during prenatal development, the signaling complex of NRG1, ErbB2, and ErbB4 controls growth of the ventricular myocardium. Additionally, this signaling complex may impact the generation of cardiomyocytes from stem and progenitor cells (63). In humans, germline mutations in the coding regions of the NRG1, ErbB2, and ErbB4 genes have not been identified. However, a recent study found a haplotype in intron 3 of ErbB4 to be associated with congenital heart disease consisting of left-sided obstructive lesions (62).

NRG1 and Its Receptors Control Postnatal Myocardial Development

In mice and rats, most cardiomyocytes withdraw permanently from the cell cycle and 80–90% become binucleated in the first 1 to 2 wk after birth (58, 82). The first indication that NRG1 may be relevant for cardiomyocyte cycling during this stage of development came from the observation that NRG1 stimulated DNA synthesis and survival in isolated neonatal rat cardiomyocytes in vitro (97). Cardiomyocyte-specific inactivation of a floxed ErbB4 gene using a β-myosin light chain-Cre (β-MLC2v) knock-in (12) led to recombination and deletion of exon 2 beginning around E8.5. This strategy yielded viable mice, which developed dilative cardiomyopathy at 3 mo of age (27). The proposed pathogenic mechanism involved abnormal intercellular electrical connectivity and compensatory cardiomyocyte hypertrophy (27). However, this cardiomyocyte-specific ErbB4 KO also showed higher cardiomyocyte nuclear ploidy detected at age 21 days, i.e., before the documented onset of the cardiomyopathy phenotype, raising the possibility that postnatal cardiomyocyte differentiation may also have been affected (27).

ErbB2, the preferred partner for ErbB4 in formation of the active heterodimer in cardiomyocytes (14), was inactivated using the β-MLC2v-Cre and muscle creatine kinase-Cre strategies (17). This study reported the development of dilative cardiomyopathy and proposed as a possible underlying mechanism an increased susceptibility to apoptosis (17). Another study, using a combination of a heterozygous germline KO and the β-MLC2v-Cre strategies, reported severe and partially lethal dilative cardiomyopathy with an onset at 2 mo of age (69). An effect on cardiomyocyte apoptosis and cycling was excluded. It should be noted that the aforementioned genetic deletion strategies, although cardiomyocyte-specific, were not inducible and do not allow definitive assessment of possible cellular effects in the second and third trimesters or early postnatal period.

The effect of inactivating ErbB4 at specific times during postnatal development on cardiac structure and function was determined in another study (6), which used a conditional strategy for inactivating the ErbB4 gene with the α-myosin heavy chain-MerCreMer (α-MHC-MerCreMer) approach (80). With the use of this strategy, ErbB4 was inactivated on the first day of life, which resulted in decreased cardiomyocyte cycling and division detected at 2.5 wk of age (6). Conversely, overexpressing the ErbB4 cDNA under control of the α-MHC promoter increased cardiomyocyte cycling and division, detected at 2.5 wk of age, which resulted in more cardiomyocytes with a smaller mean cellular volume. Because the heart weight was not affected, this suggests that the increased number of cardiomyocytes was offset by decreased cell size (6). In the absence of genetic modifications, injecting NRG1 into 3-wk-old healthy C57Bl6 mice increased cycling and divisions of cardiomyocytes (6).

This study also showed that the cellular mechanisms of NRG1/ErbB4-controlled postnatal cardiomyocyte proliferation involved the population of mononucleated cardiomyocytes (6). This subpopulation in rodents is almost 100% at birth and decreases to 10–20% in the first 2 wk of life (58, 82). In adult mice, only few mononucleated cardiomyocytes proliferated, suggesting the existence of a privileged subpopulation or an unknown limiting mechanism. Inactivating ErbB4 decreased and overexpressing ErbB4, and injecting NRG1, increased the percentage of cycling mononucleated cardiomyocytes. However, the overall percentages of mono- and binucleated cardiomyocytes remained unchanged, indicating that NRG1-stimulated cell cycling of differentiated cardiomyocytes may lead to formation of binucleated cardiomyocytes as well as cell division. This is consistent with the notion that NRG1 stimulates proliferation and differentiation in mature cardiomyocytes and is consistent with its role in stimulating differentiation of immature cardiomyocytes during early myocardial morphogenesis (30). These results indicate that a subpopulation of differentiated, proliferation-competent cardiomyocytes exists in the mononucleated pool, in agreement with the results from cats (13) and rats (51). Molecular-genetic identifiers and char-


NEUREGULIN1/ErbB4 SIGNALING AND CARDIOMYOCYTE PROLIFERATION

Back-of-the-envelope calculation of NRG1-stimulated regeneration of cardiomyocytes in mice after MI

<table>
<thead>
<tr>
<th>1 wk of treatment</th>
<th>12 wk of treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Control (BSA)</td>
<td>Test (NRG1)</td>
</tr>
<tr>
<td>BrdU+ cardiomyocytes (5 injections)</td>
<td>0.04%</td>
</tr>
<tr>
<td>H3P+ cardiomyocytes</td>
<td>0.01%</td>
</tr>
<tr>
<td>Aurora B kinase+ cardiomyocytes</td>
<td>0.008%</td>
</tr>
<tr>
<td>Number of cardiomyocyte nuclei present in LV</td>
<td>$3.6 \times 10^6$</td>
</tr>
</tbody>
</table>

|                  |
|------------------|------------------|
| Control (BSA)    | Test (NRG1)      |
| BrdU+ cardiomyocytes (5 injections) | 0.01% | 0.15% |
| H3P+ cardiomyocytes | ND | ND |
| Aurora B kinase+ cardiomyocytes | ND | ND |
| Number of cardiomyocyte nuclei present in LV | $3.8 \times 10^6$ | $5.1 \times 10^6$ |

Table 2. Back-of-the-envelope calculation of NRG1-stimulated regeneration of cardiomyocytes in mice after MI

|                  |
|------------------|------------------|
| Control (BSA)    | Test (NRG1)      |
| BrdU+ cardiomyocytes (5 injections) | 0.04% | 0.18% |
| H3P+ cardiomyocytes | 0.01% | 0.055% |
| Aurora B kinase+ cardiomyocytes | 0.008% | 0.03% |
| Number of cardiomyocyte nuclei present in LV | $3.6 \times 10^6$ | $3.1 \times 10^6$ | $3.8 \times 10^6$ | $5.1 \times 10^6$ |

Numeric data are from Bersell et al. (6) and were rounded. Corresponding results from control [(injected with bovine serum albumin (BSA)] and treated (NRG1-injected) are shown. BrdU, 5-bromo-2-deoxyuridine; H3P, phosphorylated histone H3; LV, left ventricle; ND, not done.

Theeffect of NRG1 administration on cycling and proliferation of adult cardiomyocytes was evaluated in 3-mo-old C57BL6 mice (6). The stimulation by NRG1 was inhibited by inactivating the ErbB4 gene but not augmented by increasing ErbB4 expression in cardiomyocytes. This indicates that ErbB4 was required for NRG1-stimulated cardiomyocyte cycling in vivo, but overexpressing ErbB4 did not augment the effect, suggesting that other limiting mechanisms are likely active. In adult animals, the underlying cellular mechanisms of NRG1-stimulated cardiomyocyte division involved a subpopulation of mononucleated cardiomyocytes, which have proliferative potential. This is consistent with video microscopy of cultured adult rat ventricular cardiomyocytes showing that 12.5% of mononucleated cardiomyocytes divided under NRG1 stimulation in a 6-day observation period. In vivo data in agreement with this finding include the presence of double-labeled mononucleated cardiomyocytes after sequential labeling with different thymidine analogs. This is analogous to proliferating mononucleated cardiomyocytes in growing cats (13) and peristin peptide-stimulated rat cardiomyocyte proliferation in vitro and in vivo, where mononucleated cardiomyocytes also cycle (51). Interestingly, myocardial regeneration in adult zebrafish is based on a cellular mechanism of proliferating cardiomyocytes, with almost all cardiomyocytes in zebrafish being mononucleated (90). In summary, adult mice and rats have a subpopulation of differentiated cardiomyocytes that responds to NRG1 with cell cycling and proliferation. Although humans have a higher percentage of mononucleated cardiomyocytes than rodents, the percentage of polyploid nuclei is also higher in humans, and it is currently unknown how these animal data translate into humans (53).

In vitro 5-bromo-2-deoxyuridine labeling followed by visualization of cytokinesis suggests that for NRG1-stimulated cardiomyocyte divisions, DNA synthesis precedes cytokinesis and video microscopy provides direct evidence that karyokinesis precedes cytokinesis (6). However, it is important to note that karyokinesis was not always followed by cytokinesis in cultured adult cardiomyocytes and in mouse hearts in vivo since ~50% of cell cycles were not productive and resulted in formation of binucleated cardiomyocytes (6), suggesting that karyokinesis without subsequent cytokinesis may be another NRG1-stimulated mechanism. Since it is generally accepted that binucleated cardiomyocytes represent the terminally differentiated phenotype in rodents (82), this can be interpreted as evidence for a prodifferentiation effect of NRG1.

Stimulating and assaying cardiomyocyte cycling and proliferation are experimentally challenging (2, 3, 81). The experimental parameters that may potentially influence the outcome of NRG1-stimulation with respect to cardiomyocyte proliferation are unknown. NRG1 stimulation of cardiomyocyte cell cycle activity and proliferation was demonstrated so far only in cultured adult rat ventricular cardiomyocytes in vitro and in juvenile and young adult mice in vivo [see Table 1, and Bersell et al. (6)]. In addition, all of the animal studies presented in Table 1 involved animals with experimentally induced MI, i.e., without coronary artery disease and comorbidities, in contrast to the two reported human clinical trials. It remains to be tested whether NRG1 can stimulate cardiomyocyte proliferation in aged mice, in injury models other than MI, and in humans. The effect of NRG1 injection was also evaluated in a mouse MI model (6). In this study, daily administration of NRG1 (Table 1) for 12 wk resulted in a 10% improvement of the EF, determined by echocardiography, and a significant reduction of the infarct scar size. At the cellular level, ~0.7 × 10⁶ new cardiomyocytes were generated, an increase of 17%, which was accounted for by summing up the number of cardiomyocytes predicted to be generated based on the measured phosphorylated histone H3 index over the 12-wk period (Table 2). NRG1-injected animals had smaller mean cardiomyocyte diameters and the same heart weight as controls, indicating that NRG1-administration may have an antihypertrophic effect.

It is important to note the significantly higher dose of NRG1 (100 µg/kg ip) and longer duration of administration (12 wk) used in this study (6) compared with those in the human trials.
(0.3–1.2 μg/kg iv for 10 days) and prior animal studies [3–30 μg/kg iv for 5 days; (26, 42, 60); see Table 1]. In addition, it should be noted that different versions of recombinant NRG1 have been applied (Table 1), i.e., full-length NRG1 (amino acids 2–244), comprised of the heparin-binding and the EGF-like domains and an EGF-like domain-only NRG1 (approximately, amino acids 176–246). The functional differences between the dosing and administration regimens and recombinant products are currently unknown.

The notion that NRG1 may stimulate some differentiated cardiomyocytes to divide raises the question of how they divide. In differentiated cardiomyocytes that were actively in karyokinesis, the sarcomeric Z disks and M bands were disassembled in the region of the midzone of the mitotic spindle (6). In cytokinesis, sarcomeric structures were absent from the division plane (6). Thus the observed sarcomeric disassembly was similar to the disassembly described in dividing fetal cardiomyocytes (1) and in regenerating zebrafish hearts (44). This leads to the hypothesis that the intracellular NRG1 effects must include signaling pathways that influence the integrity of the sarcomeric apparatus. These data suggest that NRG1/ErbB signaling may be directly or indirectly connected to the sarcomere structure.

A different study evaluated 10 daily injection of NRG1 in rats with MI and other models of myocardial injury (60). This aforementioned study demonstrated significant functional improvements of the combination of NRG1 with ACE inhibitor compared with a control group receiving only ACE inhibitor.

**Potential Effects of NRG1 Administration that Do Not Involve Cardiomyocyte Proliferation**

NRG1 administration may activate other cellular processes in those cardiomyocytes that do not proliferate. These processes may be relevant for understanding the effects of therapeutic strategies that target the NRG1/ErbB2/ErbB4 complex. NRG1 has been shown to be antiapoptotic in cultured adult rat ventricular cardiomyocytes via activating the Akt pathway (24). This mechanism is consistent with the cardioprotective function of endogenous NRG1, released from the vascular endothelium (16, 57), in the acute phase after experimental MI (33). However, NRG1 injection 1 wk after MI did not affect the percentage of cardiomyocyte apoptosis (6). NRG1 administration may also be involved with regulation of the structure of cardiomyocyte sarcomeres as it affects anthracyclin-induced myofibril disarray in cell culture (11, 24, 52, 77) and improves anthracycline-induced myocardial dysfunction in mice (7). However, the cardiomyocyte-specific KOs of ErbB2 and ErbB4 did not show myofibril disarray, despite having dilative cardiomyopathy (17, 27, 69). In addition, NRG1 administration alters the transcription of many genes in the heart; for example, it lowers levels of α- and β-MHC and increases cardiac MLC kinase (31) levels and phosphorylation in vivo, which may affect the molecular composition and regulation of the sarcomeres. Furthermore, NRG1 addition to isolated cardiomyocytes regulated the activity of the sarco(endo)plasmic reticulum Ca²⁺-ATPase 2, thereby improving calcium handling (8). If operative in vivo, this mechanism may improve diastolic dysfunction. In this context, it is interesting to note that the administration of NRG1 decreased inotropy in isolated papillary muscles (56). In a different report, heterozygous NRG1 KO animals displayed altered regulation of cardiomyocyte excitation and contraction by muscarinic and adrenergic agonists (67), suggesting an effect of endogenous NRG1 on autonomic control of cardiomyocyte contractile function. In summary, both endogenously produced and exogenously administered NRG1 activate many potentially beneficial processes in the heart.

Thus far, only the cardiomyocyte-autonomous effects of NRG1 administration have been considered. However, NRG1, whether endogenously produced or administered, may also affect cells other than cardiomyocytes. Perhaps NRG1 stimulates differentiation of resident stem and progenitor cells into cardiomyocytes, as suggested by its cardiomyogenic effect in embryonic stem cell cultures (84, 89, 98). However, the detection of cell cycle events in (genetically labeled) cardiomyocytes suggests this is unlikely to be the case in adult mice in vivo, although effects on immature progenitor cells and cardiomyocytes may coexist (6). An additional important consideration is the possibility that NRG1 may not only act on cells of the cardiomyocyte lineage but rather on resident noncardiomyocytes, which are often generally called cardiac fibroblasts (45, 95). This possible effect of NRG1 on cardiac fibroblasts may involve complex and currently unknown paracrine and juxtacrine pathways (18, 29, 65). In addition, it has been proposed that NRG1-administration may regulate angiogenesis, which may in turn contribute to its beneficial effects (34, 38, 46, 75).

The fact that NRG1 administration has multiple effects in the heart is not sufficient to conclude that it is the only or the physiological ligand of ErbB4 in the myocardium. In fact, HB-EGF, a high-affinity ligand for the EGF receptor (EGFR, also called ErbB1) and ErbB4, is expressed in the heart (40, 41). Conditional inactivation of HB-EGF induces cardiac dysfunction and dilative cardiomyopathy (41), but the effect of administration of HB-EGF on cardiac structure and function in myocardial disease models is unknown. Although HB-EGF stimulated cell-cycle activity in embryonic cardiomyocytes in vitro (37), its effect in adult cardiomyocytes was small compared with NRG1, fibroblast growth factor, and peristin peptide (6). Furthermore, the EGFR (ErbB1), which serves as the primary receptor for HB-EGF, has been linked to cardiomyocyte hypertrophy (79), suggesting that differences may exist between the cellular effects of NRG1 and HB-EGF on cardiomyocytes.

**Effects of NRG1 Administration Outside of the Heart**

In light of efforts to advance NRG1 administration into a clinical therapy, it is important to consider the potential effects outside of the heart, which may give rise to side effects. Since both the nervous system and the breast gland express NRG1 receptors in adults, these organs may show side effects. Injection of NRG1 and ErbB receptor antagonists into the rostral ventrolateral medulla, an important region involved in central cardiovascular regulation, affected heart rate and blood pressure (61). Although it is unknown whether NRG1 administered by injection into the peritoneum or blood stream is able to cross the blood-brain barrier, these findings and the association between ErbB signaling and mental disorders (15) suggest the potential for side effects on the nervous system.
Since NRG1 stimulates cellular proliferation, a theoretical risk for cancer growth exists. However, it is important to note that the mechanism of stimulation of cancer growth by ErbB overexpression is constitutive receptor activity, i.e., ligand independent (9, 14). In contrast, physiological ErbB2 or ErbB4 action is ligand dependent. This fundamental difference may explain why tumor formation after long-term NRG1 administration has not been reported.

Summary

The in vivo and in vitro studies discussed in this article collectively help us to appreciate the role of NRG1/ErbB4 signaling in cardiomyocyte proliferation. The mechanisms of action of endogenously produced as well as administered recombinant NRG1 in the mammalian heart are beginning to be understood, and stimulation of cardiomyocyte proliferation may be part of it. Fundamental research will be necessary to map out in detail the mechanisms of action, both for endogenous regulation and for stimulation of cardiomyocyte proliferation with recombinant NRG1. This research should help in fulfilling the promise of therapeutic approaches to treating heart failure with recombinant NRG1 preparations, a strategy that awaits validation in humans.

ACKNOWLEDGMENTS

We apologize to the many scientists whose work we were not able to credit because of space restrictions. Original work has been cited at the expense of many excellent reviews. We thank our colleagues for many stimulating suggestions and helpful discussions and thank B. Polizziotti, S. Suresh, C. Edwards, and K. Bersell for comments on this text.

GRANTS

Our research was supported by the Department of Cardiology and the Translational Investigator Program (Children’s Hospital Boston); National Heart, Lung, and Blood Institute Grants K08-HL-085143 and R01-HL-106302; the Children’s Cardiomyopathy Foundation; and the Geneen Trust.

DISCLOSURES

Children’s Hospital Boston has filed a patent application on the use of NRG1 to treat heart failure. At this point, it is not clear whether the patent will be granted nor whether there will be royalties.

AUTHOR CONTRIBUTIONS

B.W. and B.K. conception and design of research; B.W. performed experiments; B.W. and B.K. interpreted results of experiments; B.W. prepared manuscript; B.W. and B.K. edited and revised manuscript; B.W. and B.K. approved final version of manuscript.

REFERENCES


53. Roger VL, Go AS, Lloyd-Jones DM, Benjamin EI, Berry JD, Borden WB, Bravata DM, Dai S, Ford ES, Fox CS, Fullerton HJ, Gillespie C,


